About OA
OA is a condition in which the cartilage, a material that cushions the joints, breaks down. This leads to stiffness, inflammation, pain, and loss of joint movement. The exact etiology of OA is not fully understood. Obesity, overuse of the joint, weak thigh muscles, aging, and genetics are some of the common risk factors of OA; OA symptoms usually develop progressively. At first, there may be stiffness that appears to be more a niggle than a medical concern. Treatment is given depending on the affected joint, including the hand, wrist, neck, back, knee, and hip, and involves medication and exercise.
TechNavio's analysts forecast the Global OA market to grow at a CAGR of 8.55 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global OA market for the period 2015–2019. To calculate the market size, the report considers revenue generated from the sales of drugs used in the symptomatic treatment and therapeutics of OA that are available in the market. The market can be divided into three segments: Anti-inflammatories, Pain Relievers, and Drugs to Restore Articular Cartilage.
TechNavio's report, the Global OA Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global OA market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Abbott Laboratories
• Johnson & Johnson
• Novartis
• Pfizer
Other Prominent Vendors
• Abiogen Pharma
• Ampio pharmaceuticals
• BioDelivery Sciences International
• CrystalGenomics
• Daiichi Sankyo
• Eli Lilly
• Horizon Pharma
• Iroko Pharmaceuticals
• Merck
• Nuvo Research
• Regeneus
• Sanofi
• SantoSolve
• Smith & Nephew
• Winston Pharmaceuticals
Market Driver
• Increase in Global Aging Population
• For a full, detailed list, view our report
Market Challenge
• Low Treatment Seeking Rate
• For a full, detailed list, view our report
Market Trend
• Increased Competition
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Understanding the Disease
06.2 Etiology and Pathophysiology
06.3 Epidemiology
06.3.1 Global Prevalence of Osteoarthritis
06.3.2 Prevalence of Osteoarthritis in US
06.3.3 Prevalence of Osteoarthritis in UK
06.3.4 Prevalence of Osteoarthritis in Canada
06.4 Risk Factors
06.5 Symptoms
6.6 Diagnosis
06.6.1 Clinical History
06.6.2 Physical Examination
06.6.3 Diagnostic Imaging Techniques
06.7 Management of Osteoarthritis
06.7.1 Non-pharmacological Therapy
06.7.2 Pharmacological Therapy
06.7.3 Surgical Treatment
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Osteoarthritis Market in US
07.3.1 Market Size and Forecast
07.4 Five Forces Analysis
08. Osteoarthritis Pipeline Assessment
09. Market Segmentation by Drug Class
10 Geographical Segmentation
11 Buying Criteria
12 Market Growth Drivers
13 Drivers and their Impact
14 Market Challenges
15 Impact of Drivers and Challenges
16 Market Trends
17 Trends and their Impact
18 Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.2.1 Abbott Laboratories
18.2.2 Johnson & Johnson
18.2.3 Novartis
18.2.4 Pfizer
18.3 Other Prominent Vendors
19 Key Vendor Analysis
19.1 Abbott Laboratories
19.1.1 Key Facts
19.1.2 Business Description
19.1.3 Business Segmentation
19.1.4 Business Strategy
19.1.5 Revenue by Business Segmentation
19.1.6 Revenue Comparison 2011 and 2012
19.1.7 Revenue by Geographical Segmentation
19.1.8 Key Information
19.1.9 SWOT Analysis
19.2 Johnson & Johnson
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Segmentation by Revenue 2013
19.2.4 Business Segmentation by Revenue 2012 and 2013
19.2.5 Geographical Segmentation by Revenue 2013
19.2.6 Business Strategy
19.2.7 Recent Developments
19.2.8 SWOT Analysis
19.3 Novartis
19.3.1 Key Facts
19.3.2 Business Description
19.3.3 Business Segmentation
19.3.4 Revenue by Business Segmentation
19.3.5 Revenue Comparison 2012 and 2013
19.3.6 Sales by Geography
19.3.7 Business Strategy
19.3.8 Key Developments
19.3.9 SWOT Analysis
19.4 Pfizer
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Business Segmentation by Revenue 2013
19.4.4 Business Segmentation by Revenue 2012 and 2013
19.4.5 Geographical Segmentation by Revenue
19.4.6 Business Strategy
19.4.7 Key Developments
19.4.8 SWOT Analysis
20 Other Reports in this Series
List of Exhibits:
Exhibit 1: Market Research Methodology
Exhibit 2: Etiology and Pathophysiology of Osteoarthritis
Exhibit 3: Global Prevalence of Osteoarthritis 2014-2019 (million)
Exhibit 4: Prevalence of Osteoarthritis in US 2009
Exhibit 5: Prevalence Rate of Osteoarthritis in US 2009
Exhibit 6: Prevalence of Osteoarthritis in UK 2013
Exhibit 7: Prevalence of Current and Future Osteoarthritis Cases by Gender in Canada 2010-2040
Exhibit 8: Diagnostic Imaging Techniques for Osteoarthritis
Exhibit 9: Management of Osteoarthritis
Exhibit 10: Global Osteoarthritis Market 2014-2019 (US$ billion)
Exhibit 11: Osteoarthritis Market in US 2014-2019 (US$ billion)
Exhibit 12: Segmentation of Global Osteoarthritis Market by Drug Class
Exhibit 13: Segmentation of Global Osteoarthritis Market by Geography 2014
Exhibit 14: Worldwide Estimated Growth of Osteoarthritis Population 2010-2020 (Age Groups in Year)
Exhibit 15: Prevalence of Osteoarthritis 2012 and 2022 (million)
Exhibit 16: Unmet Medical Needs with Current Osteoarthritis Treatments
Exhibit 17: Global Incidence of Osteoarthritis in Overweight and Normal Weight Individuals 2013 (Percent)
Exhibit 18: Future Therapeutics in Treatment of Osteoarthritis
Exhibit 19: Abbott Laboratories: Revenue Segmentation 2013
Exhibit 20: Abbott Laboratories: Product Profile
Exhibit 21: Johnson & Johnson: Sales by Therapeutic Area (Pharmaceuticals) 2013
Exhibit 22: Product Profile: Johnson & Johnson (Dolormin Gel)
Exhibit 23: Product Profile: Johnson & Johnson (Monovisc)
Exhibit 24: Product Profile: Johnson & Johnson (Orthovisc)
Exhibit 25: Product Profile: Johnson & Johnson (Tolectin)
Exhibit 26: Product Profile: Novartis
Exhibit 27: Global Revenue of Voltaren 2010-2013 (US$ million)
Exhibit 28: Revenue of Voltaren in US 2011-2013 (US$ million)
Exhibit 29: Product Profile: Novartis
Exhibit 30: Product Profile: Pfizer (Ansaid)
Exhibit 31: Product Profile: Pfizer (Arthrotec)
Exhibit 32: Product Profile: Pfizer (Celebrex)
Exhibit 33: Global Revenue of Celebrex 2010-2013 (US$ million)
Exhibit 34: Product Profile: Pfizer (Daypro)
Exhibit 35: Product Profile: Pfizer (Feldene)
Exhibit 36: Product Profile: Pfizer (Motrin)
Exhibit 37: Product Profile: Pfizer (Ponstel)
Exhibit 38: Abbott Laboratories: Business Segmentation
Exhibit 39: Abbott Laboratories: Revenue by Business Segmentation 2012
Exhibit 40: Abbott Laboratories: Revenue by Business Segmentation 2011 and 2012 (US$ million)
Exhibit 41: Abbott Laboratories: Revenue by Geographical Segmentation 2012
Exhibit 42: Johnson & Johnson: Business Segmentation by Revenue 2013
Exhibit 43: Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 44: Johnson & Johnson: Geographical Segmentation by Revenue 2013
Exhibit 45: Novartis: Business Segmentation
Exhibit 46: Novartis: Revenue by Business Segmentation 2013
Exhibit 47: Novartis: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 48: Novartis: Revenue by Geographical Segmentation 2013
Exhibit 49: Pfizer: Business Segmentation by Revenue 2013
Exhibit 50: Pfizer: Business Segmentation by Revenue 2012 and 2013
Exhibit 51: Pfizer: Geographical Segmentation by Revenue 2013
